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Abstract 20 
Clostridium difficile (Peptoclostridium difficile) is a common health care associated infection 21 
with a disproportionately high incidence in elderly patients. Disease symptoms range from 22 
mild diarrhoea through to life threatening pseudomembranous colitis. Around 20% of patients 23 
may suffer recurrent disease which often requires re-hospitalisation of patients. 24 
C. difficile was isolated from stool samples from a patient with two recurrent C. difficile 25 
infections. PCR-ribotyping, whole genome sequencing and phenotypic assays were used to 26 
characterise these isolates. 27 
Genotypic and phenotypic screening of C. difficile isolates revealed multiple PCR-ribotypes 28 
present, and the emergence of rifamycin resistance during the infection cycle.  29 
Understanding both the clinical and bacterial factors that contribute to the course of recurrent 30 
infection could inform strategies to reduce recurrence. 31 
 32 
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Introduction 40 
Clostridium difficile (Peptoclostridium difficile) is a common health care associated infection 41 
with a disproportionately high incidence in elderly patients. Recurrent Clostridium difficile 42 
infection (CDI) is known to occur in approximately 20% of patients following withdrawal of 43 
treatment antibiotics (1), however, this may rise to 65% if a patient has a prior history of CDI 44 
(2). Recurring CDI not only causes distress to patients, but is also a substantial burden on the 45 
healthcare system due to the increased cost (3) associated with possible prolonged stay or re-46 
admission of a patient to hospital and the re-administration of diagnostic tests and antibiotics 47 
(4). Collaborations between clinicians and researchers are contributing to the knowledge of 48 
how both the host and bacterium are affecting recurrent disease, in order to reduce recurrence 49 
rates, through personalised patient care regimens (5).   50 
In this study multiple stool samples from a patient enrolled in a clinical trial (see case 51 
information) were collected and C. difficile was isolated. The strains isolated from these 52 
samples were then phenotypically and genotypically characterised to deduce if changes in the 53 
C. difficile strain genotype and phenotype could have contributed to recurrent infection. 54 
Case 55 
A male participant (01008) aged 85 years who had a history of chronic kidney disease and 56 
was on multiple long term medication including, bumetanide, candesartan, digoxin, 57 
simvastatin, doxazosin, ferrous fumarate and prednisolone. Three months prior to trial 58 
enrolment the participant received cefuroxime and gentamicin for a urinary tract infection. 59 
One month prior to trial enrolment he was admitted to the hospital, where he received 60 
clindamycin (both orally and intravenously) for an infected leg ulcer.  61 
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In June 2013, after being re-admitted to hospital, he was diagnosed with CDI (Table 1; 62 
sample A), was treated with metronidazole (MET) and discharged. He was diagnosed again 63 
with CDI in July (Table 1; sample B) and was again treated with MET. 64 
In July 2013, within 5 days of cessation of successful treatment of CDI with MET (defined as 65 
cessation of diarrhoea for 2 or more days with no loose stools, assessed), he was enrolled on a 66 
randomised double blind placebo controlled clinical research trial, aimed at using Rifaximin 67 
for reducing relapse of Clostridium associated diarrhoea (RAPID- NCT01670149).  A 68 
simplified study time line of stool sample collection is outlined in Figure 1.  69 
The participant successfully provided one trial stool sample (Table 1; sample C). However 70 
within 10 days, suffered another diarrhoeal episode (Table 1; sample D), which was initially 71 
toxin negative as confirmed using the C. DIFF QUIK CHEK complete kit (Alere) and PCR 72 
using the BD MAX™ Cdiff kit (BD Molecular Diagnostics). However, 6 days after sample D 73 
he provided another sample (Table 1; sample E) which was toxin positive and therefore 74 
defined as relapse according to the RAPID trial protocol (onset of >3 loose bowel movements 75 
per day for at least 2 consecutive days combined with a positive toxin assay (with or without 76 
a positive C. difficile culture)). He was treated with MET and over 8-10 weeks provided two 77 
more trial samples (Table 1; samples F & G). Participant notes revealed that during the period 78 
when he provided more RAPID samples, he was again diagnosed with CDI (September) and 79 
treated with Vancomycin (VAN). 80 
The participant was again admitted to hospital and treated with tazocin and subsequently 81 
suffered another CDI (Table 1; sample H), around his time of death, in January 2014 due to 82 
multiple organ failure. As this was a randomised double blind placebo controlled clinical 83 
research trial, it was not known if participant 01008 was on placebo or rifaximin therapy, at 84 
the point at which this research was undertaken. 85 
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Methods 86 
A total of eight stool samples were collected from the participant (Table 1). These included 87 
diagnostic specimens from the Queens Medical Centre (QMC) microbiology department, 88 
Nottingham, that were proven C. difficile toxin positive by using the C. diff Quik Chek 89 
complete kit (Alere) and PCR using the BD MAX™ Cdiff kit (BD Molecular Diagnostics). 90 
C. difficile was cultured from ~ 300mg of stool using a previously published protocol (6). 1-91 
20 C. difficile colonies were isolated per sample (Table 2). 92 
C. difficile typing 93 
After 48 hours (hrs) of growth on Cefoxitin Cycloserine Egg Yolk (CCEY) (6) agar, up to 20 94 
individual C. difficile colonies from each stool specimen were inoculated into a single well of 95 
a 96-well plate containing 200 µL anaerobic Brain Heart Infusion (Oxoid) plus 0.1% L-96 
cysteine (Sigma) (BHIS) broth, leaving one well blank as a control.  The plate was sealed 97 
with a breathable sterile film and incubated for 24 hrs in an anaerobic workstation (Don 98 
Whitley) (CO2:H2:N2 (80:10:10 vol:vol:vol,). After 24 hrs the wells were checked for 99 
turbidity. Overnight cultures were then diluted 10-fold with sterile PCR grade water into a 100 
fresh 96-well plate, sealed with film and stored at -20°C until required. One drop of 100% 101 
glycerol was added to the BHIS cultures and the plate was stored at -80°C until required. 102 
Every colony that was isolated from each stool sample was subjected to in-house ribotyping 103 
with the diluted cultures as mentioned above. PCR amplification of the 16s rRNA intergenic 104 
spacer region was carried out according to a modified protocol obtained from the former C. 105 
difficile ribotyping laboratory in Cardiff (Supplementary data). PCR-ribotype profiles were 106 
analysed with a QIAxcel capillary Electrophoresis machine (Qiagen) using the OL400 107 
programme with the QX 15bp-1Kb alignment marker and the QX Size Marker 50 bp –800 108 
bp. Individual profiles were assessed, and then one isolate from each distinct typing profile 109 
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that had been obtained from each stool sample, was re-cultured onto BHIS-CC agar and 110 
stored as a glycerol stock. 111 
These stock strains were sent for official ribotyping via the C. difficile ribotyping network 112 
(CDRN) service in Leeds and used for downstream characterisation. 113 
Phenotypic Characterisation 114 
Growth, sporulation and toxin A and B ELISAs were performed on all isolates. 115 
(Supplementary data) 116 
Antibiotic Susceptibility 117 
Isolated strains were tested for antibiotic resistance to metronidazole (MET) and vancomycin 118 
(VAN), using the E-test method (Oxoid) and Rifampicin (RIF) and Rifaximin (RFX) 119 
resistance by broth dilution (see supplementary data) using a 2-fold antibiotic dilution range 120 
from 512 - 0.5 µg/ml. C. difficile strains 630∆erm, 630 wild type (WT) and R20291 were 121 
used as controls. Guideline MIC breakpoints for RIF and RFX were taken from (7), where 122 
isolates with  MICs ≥32 μg/ml were considered resistant. Intermediate resistance was defined 123 
as an MIC of 0.003–32 µg/mL (8). 124 
Genotypic Characterisation 125 
DNA was extracted from strains using a Phenol:Chloroform:Isoamyl alcohol (25:24:1) 126 
saturated with 10 mM Tris, pH 8.0, 1 mM EDTA (Sigma) extraction method adapted from 127 
(9)(See supplementary data).  128 
Whole Genome comparison 129 
Genomic DNA was sent for Illumina sequencing using MisSeq 250-PE technology, 130 
(DeepSeq, University of Nottingham). DNA from one of the isolates from sample A (earliest 131 
RT002 isolate), and sample E (earliest RT014 identified) designated E2 were also sent for 132 
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Pacific Bioscience (PacBio) Sequencing (McGill University and Genome Québec Innovation 133 
Centre). Paired-end reads from the MiSeq runs were mapped to PacBio contigs using CLC 134 
Genomics Workbench Version 8.0.2 (Qiagen).  135 
 136 
Concordance of PacBio and Illumina sequencing 137 
To demonstrate the concordance of two different sequencing methods (especially over 138 
homopolymer regions), Illumina paired-end sequencing reads from isolate A and E2 were 139 
mapped back to the Pacbio reference contigs. Basic variant detection (CLC Genomics 140 
Workbench Version 8.0.2 [Qiagen]) was used to call single nucleotide variations (SNVs), 141 
insertions and deletions. All default parameters were kept the same apart from the minimum 142 
frequency setting in the coverage and count filters process. The minimum frequency setting 143 
was changed to 50% to try and capture as many high quality changes as possible. 144 
Results 145 
Ribotype of Clostridium difficile Isolates obtained from stool 146 
During the course of infection two distinct C. difficile PCR-ribotypes were isolated (Table 2). 147 
The predominant PCR-ribotype occurring during the infection was RT002. Co-infection of 148 
the participant with a second PCR-ribotype (RT014), was detected in stool sample E. This 149 
sample was a diagnostic sample obtained after the participant had suffered the first relapse 150 
(Table 2). However, it cannot be deduced whether this PCR-ribotype was present in earlier 151 
samples (i.e. C or D) due to the low number of colonies obtained from the stools of these 152 
samples. The RT014 isolate, may therefore, have been present at low frequency in these 153 
samples.  154 
 155 
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Isolate Growth, Sporulation and toxin quantification 156 
All isolates showed similar growth profiles in both BHIS and TY (data not shown) except 157 
isolate G. This isolate had a shorter stationary phase when grown in BHIS and reduced 158 
growth in TY broth. However, this did not affect sporulation and toxin titre as there were no 159 
significant differences in these phenotypes, between any of the isolates (data not shown). 160 
Pacific Bioscience and Illumina MiSeq Sequencing of RT002 and RT014 isolates  161 
The PacBio sequencing was able to assemble the genome of isolate A into four contigs 162 
(Table 3) and isolate E2 into one contig of 4,330,205bp. Contigs were identified by means of 163 
Blast searches using the dc-megablast option against the nt database. BLAST analysis of the 164 
one contig from isolate E2 suggests that it shares sequence similarity with the 165 
Peptoclostridium difficile genome assembly CD630DERM, chromosome : 1 (LN614756.1). 166 
The individual contigs were annotated using RAST (10) and used as reference strains for 167 
Illumina read mapping of all isolates. 168 
Over 97% of reads from seven RT002 isolates (A, B, C, D, E1, F & G) and >97% of reads 169 
from two RT014 isolates (E2 and H) mapped to the reference PacBio contigs for the 170 
corresponding PCR-ribotype.  171 
Concordance of PacBio and Illumina sequencing 172 
Nine SNVs were identified in all the RT002 genomes and twelve SNVs were detected when 173 
Illumina MiSeq reads were mapped back to their respective PacBio contigs. All SNVs of the 174 
RT002 isolates occurred in the first contig, which represented the main C. difficile 175 
chromosome. All the SNVs from both RT002 and RT014 isolates occurred in homopolymer 176 
regions of ≥4 nucleotides in length. PCR amplification and Sanger sequencing of all the 177 
regions in isolate A and E2 that contained the SNVs confirmed that they were true SNVs. 178 
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Accordingly, the reference sequences A and E2 were corrected and the sequence reads from 179 
the subsequent isolates (B-G) were remapped. 180 
SNV detection in RT002 isolates 181 
Basic variant detection was performed on the reads to assess whether the sequential isolates 182 
contained additional changes from the original (A) isolate (Table 4). Isolate B did not contain 183 
any additional SNVs. Isolate C contained one additional SNV. The A>G nucleotide change 184 
did not result in an amino acid change. Isolate D and E1 both contained the same four 185 
additional SNVs compared to isolate A, two of which were non-synonymous and found in 186 
oppF and rpoB (Table 4). The former encodes an oligotransport-ATP binding domain, while 187 
the latter encodes a DNA-directed RNA polymerase beta subunit. These two isolates did not 188 
contain the SNV found in isolate C. Isolate F contained five SNVs compared to A, however, 189 
these were not the same as any SNVs in previous isolates. One of the SNVs in isolate F was 190 
found in the same gene (rpoB), but not at the same position as in isolates D and E1. Variant 191 
detection in isolate G, produced 70 SNVs. Closer inspection of these SNVs revealed that 64 192 
were detected at low frequency in poorly mapped regions and were probably not real. Thus, 193 
this isolate had six SNV differences compared to isolate A and B (Table 4). Five SNVs were 194 
in the same regions as isolate F with two of the SNVs, in a hypothetical protein and rpoB, 195 
being in the exact same location as in isolate F. (Table 4) 196 
SNV detection in RT014 isolates 197 
Six additional SNVs were found in isolate H compared to isolate E2. Five of these SNVs 198 
were in a gene annotated as fliK, but which is not actually part of the flagellar operon. Only 199 
two of these five SNVs were non-synonymous and occurred at a frequency <52% and with an 200 
average quality of <22. Closer inspection of this region revealed that the sequence quality 201 
was poor most likely due to it being repetitive, suggesting that these SNVs were not likely to 202 
 o
n
 O
ctober 20, 2016 by UNIV O
F BIRM
ING
HAM
http://jcm.asm.org/
D
ow
nloaded from
 
 
 
be real. Thus, only one additional T >C SNV was identified. The SNV was in an intergenic 203 
region of the genome of isolate H, at position 2562170 bp, upstream of of a gene encoding a 204 
small hypothetical protein that shows similarity to a putative membrane protein. 205 
Isolate Antibiotic resistance  206 
No isolate showed resistance to MET (breakpoint considered as resistant ≥2 µg/ml) or VAN 207 
(breakpoint considered as resistant ≥4 µg/ml) (data not shown).  Early RT002 isolates A, B 208 
and C, showed complete susceptibility to rifampicin (RIF) and rifaximin (RFX) (Figs. S1a, 209 
S1b, S2a & S2b). However, RT002 isolates D (from the relapse sample) and E1 (post relapse 210 
sample) showed high resistance (≥ 256 µg/ml) to RIF and RFX (≥128 µg/ml), whilst RT002 211 
isolates F and G showed intermediate resistance to both (RIF;≥4 µg/ml, RFX;≥16 µg/ml ). 212 
The RT014 isolates (E2 and H) and control strains were fully susceptible to RIF and RFX 213 
(>0.5 µg/ml). (Figs. S1a, S1b, S2a & S2b). 214 
Frequency of rpoB SNVs in all cultured A to G RT002 isolate samples  215 
To try and discern whether there were two distinct populations of RIF and RFX resistant 216 
RT002 isolates, the region in rpoB that contained the SNVs identified in Table 4, was 217 
amplified from every isolate with a PCR-ribotype banding pattern confirmed with the 218 
QIAxcel (Table 1). The PCR amplified DNA fragment was sent for Sanger sequencing and 219 
the sequences were checked for the above SNVs. The frequency of these SNVs in each 220 
isolate is detailed in Table 5. 221 
 Discussion 222 
The recurrent infection suffered by participant 01008 is one which is endured by up to 20% 223 
of patients suffering from CDI (1). Over a 180 day period this particular individual relapsed 224 
twice with CDI and presented with co-infection of two different PCR-ribotypes. At one 225 
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particular point during the infection theparticipant also, either acquired a RT002 isolate 226 
which was resistant to rifamycins (re-infection), or the original isolate developed rifamycin 227 
resistance, due to microevolution (relaspe). The combination of these factors could have 228 
contributed to the persistence of this participant’s infection. 229 
The nature of the RAPID trial is to recruit participants at the end of their standard CDI 230 
therapy, when the patient has been assessed as being resolved of CDI. The participant is then 231 
started on a regimen of either RFX or placebo for four weeks during which stool samples are 232 
collected. The participant is then followed up for another eight weeks during which more 233 
stool is collected. As this was a randomised double blind placebo controlled clinical research 234 
trial, at the point at which this research was undertaken, it was not known if participant 01008 235 
was on placebo or rifaximin therapy. 236 
What is clear from this data, is that even though this participant was deemed to have resolved 237 
symptoms of CDI prior to trial enrolment, there was still a low level of C. difficile in the stool 238 
(as indicated by the isolation of C. difficile from sample C) and in this participant it may have 239 
contributed to the recurrence of disease. There is further genetic evidence to suggest that the 240 
RT002 isolate found in the pre-enrolment diagnostic specimens (A and B) had persisted, at 241 
least until the next sample specimen (C). According to others (11-13) genetically identical 242 
strains differ by ≤2 SNVs and there was only one SNV difference between isolate A/ B and 243 
C.  At some point during the time between sample C and sample D, participant 01008 either 244 
acquired a genetically distinct RT002 isolate (re-infection) with resistance to RIF and RFX, 245 
or the original RT002 isolate evolved to become RIF and RFX resistant (≥256 µg/ml and 246 
(≥128 µg/ml respectively) relapse. Prior to sample D all isolates from samples A, B and C did 247 
not contain SNVs in the rpoB gene (Table 5), supporting the notion that participant 01008 248 
was probably colonised with one population of non-resistant RT002 isolates at that time of 249 
the infection. In other studies (11, 12) genetically distinct isolates are differentiated by >10 250 
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SNVs. Here isolate D differed by only four SNVs compared to isolate A,B and C and within 251 
the population of isolates from sample D (Table 5) one isolate did not contain the SNV in the 252 
rpoB gene. Thus, it is not possible to deduce whether this was a newly acquired isolate or 253 
whether the initial strain had mutated. It is possible that the RT002 isolate in this infection 254 
was under high antibiotic selection pressure and thus may have mutated more rapidly than 255 
others have calculated for strains not under intense selection pressure(14). 256 
Whole genome sequencing of isolates A-H revealed that the probable cause of RIF and RFX 257 
resistance in isolate D, was a C>A SNV at position 1465bp in the rpoB gene, encoding a 258 
DNA-directed RNA polymerase beta subunit (Table 4).  Mutations in rpoB have been 259 
identified in C. difficile (7, 8) and also occur in multi-drug resistant strains of Mycobacterium 260 
tuberculosis (MTB) (15) within a small 23 amino acid region from position 511-533 (16). 261 
This suggests a common mechanism by which resistance to this antibiotic occurs in multiple 262 
bacterial species. 263 
The SNV in isolate D resulted in a Glutamine > Lysine amino acid change at position 489 of 264 
the peptide. It is known that the Glutamine residue at the corresponding position of RpoB in 265 
Thermus aquaticus directly binds to rifampicin (7, 17). Thus, it is likely that this SNV is 266 
directly responsible for resistance to RIF and RFX in this isolate and this may have played a 267 
role in the first relapse suffered by this participant. A subsequent stool specimen from 268 
participant 01008 revealed the presence of a genetically identical RT002 isolate (E1) to 269 
isolate D, which also shared the same SNV change in rpoB and was also RIF and RFX 270 
resistant (≥256 µg/ml and ≥128 µg/ml respectively ). The sample also contained another 271 
ribotype (RT014 - E2). Isolate E2 was fully sensitive to RIF and RFX.  If participant 01008 272 
was on RFX therapy then it is unlikely that isolate E2 contributed to the relapse, as clearly the 273 
vegetative form of the isolate is susceptible to the rifamycins and would have been killed. 274 
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However, whether or not the isolate was present just prior to relapse, is not discernible, as it 275 
was only possible to isolate one colony from the pre-relapse sample C. The RT014 isolate 276 
(E2) may have been present in the host at low levels in the spore form, evading the effects of 277 
possible antibiotic therapy, and persisting until a time when it could germinate and grow. 278 
This hypothesis is supported by the emergence of the RT014 (H) isolate in the final stool 279 
sample which was genetically indistinct from isolate E2.  280 
Isolates D and E1 also shared a SNV in the oligotransport-ATP binding domain of oppF 281 
(Table 4), which belongs to an operon of oligopeptide permease (opp) genes that are involved 282 
in regulating sporulation (amongst other processes) in some species of Bacillus and 283 
Clostridium (18, 19). In vitro sporulation studies on all isolates revealed no significant 284 
difference (data not shown) in the rate of sporulation between isolate D, E1 and all other 285 
isolates. However, this data may not be representative of in vivo sporulation characteristics; 286 
therefore it cannot be conclusively proven that this SNV had no effect. The opp operon is 287 
involved in other processes in other organisms, for example competence in Bacillus and 288 
Streptococcus species, plasmid transfer in Enterococcus faecalis, and the expression of 289 
virulence factors in Bacillus thuringiensis (18, 20). SNVs in this region may, therefore, have 290 
a yet undiscovered role in C. difficile virulence and could present a further avenue of 291 
research. 292 
The next specimen provided by the patient revealed the presence of an RT002 isolate (F) with 293 
five additional SNVs compared to isolate A, B and C. Four of the SNVs were completely 294 
different to the previous isolate (E1) and isolate D. However, one SNV was again located in 295 
rpoB, at a different position (1475bp), resulting in an A>T change that caused an amino acid 296 
change from aspartic acid > valine at position 492 of the peptide. The substitution of this 297 
aspartic acid residue to other amino acids, including valine, has been shown to result in RIF 298 
resistance in Staphylococcus aureus (7, 21). Unlike the RpoB amino acid changes in isolates 299 
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D and E1, the RpoB amino acid change in isolate F, apparently conferred only intermediate 300 
resistance to RIF(≥ 4 µg/ml) and RFX (≥µg/ml ). The SNV at this position was also shared 301 
by the final RT002 isolate found in sample G, which showed the same level of resistance to 302 
RIF and RFX. Whether or not this level of resistance would be sufficient to contribute to the 303 
persistence of the organism in the colon is unclear, but there is clearly selective pressure for 304 
this mutation occurring either in the host or within the C. difficile population found at the 305 
QMC in Nottingham.   306 
The presence of a SNV in the same gene (rpoB), but at different positions within the RT002 307 
isolates, supports the notion that two distinct subpopulations of RIF and RFX resistant RT002 308 
isolates could have co-existed in this participant. Further sequencing of this region in sample 309 
E RT002 isolates, revealed that they all shared the same C>A SNV. However, one of the 310 
fifteen sample F isolates cultured (Table 5) contained the C>A SNV found in sample E 311 
isolates and not the A>T SNV found in the remaining F isolates, indicating that two sub-312 
populations of RT002 isolates could have potentially co-existed at this point. Amongst the 313 
sample G isolates, there were equal population of isolates with and without any SNVs in 314 
rpoB. This either indicates the persistence of the initial susceptible isolate in the gut, or that at 315 
the time sample G was taken the population was in a transient state of mutation.  316 
It is poignant to note that other studies have documented cases of C. difficile rifamycin 317 
resistance after chaser therapies using rifaximin (8, 22, 23). One of these studies has linked 318 
this resistance to mutations in RpoB (8) that have been identified by others (7). The study by 319 
Curry et al. (8) indicates that in their study population, more than one-third of isolates were 320 
resistant to rifaximin and this is something which could be looked at in a wider population of 321 
participants on the RAPID trial, as it may prompt clinicians to alter dosing regimen if the 322 
therapy was approved for use in patients suffering recurrence. 323 
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Conclusion 324 
This case study has presented insight in to the course of recurrent infection caused by C. 325 
difficile. In this case it was difficult to ascertain whether, in this particular individual, the C. 326 
difficile strain was evolving. However, it did reveal the possible presence of multiple isolates 327 
with SNVs causing distinct fitness advantages. The fact that this participant was enrolled in a 328 
trial to investigate the use of RFX to prevent recurrence suggests that we should be 329 
monitoring mutations in the rpoB gene more closely in the isolates from trial patients, as a 330 
side effect of this therapy could be the increased selection for RFX resistant C. difficile 331 
strains. This is of importance to clinicians as it may directly impact the antibiotic regimen 332 
they use to treat their patient.  333 
The advent of high throughput technologies will allow for more in depth screening of 334 
samples to elucidate the true genetic fingerprint of the isolates found during infection. When 335 
coupled with in-depth microbiome analysis of the host, this may allow researchers to more 336 
fully comprehend the overall picture of recurrent infection and in turn this translate this 337 
information to clinicians, in order to manage ‘at risk’ patients more effectively and reduce the 338 
morbidity and economic burden of C. difficile within the healthcare system. 339 
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 447 
               Table 1- Description and date of sample collection for participant 01008 on the RAPID trial 448 
ID Specimen Sample collection date 
A 1st diagnostic sample* 21/6/13 
B 2nd diagnostic sample* 1/7/13 
C Week 0 (visit 1) RAPID sample 9/7/13 
D Relapse sample 1 19/7/13 
E Diagnostic sample post relapse sample 1* 27/7/13 
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F Week 4 (visit 3) RAPID sample 7/8/13 
G Week 12 (Visit 5) RAPID sample 2/10/13 
H Relapse sample after week 12 (visit 5) RAPID sample 4/1/14 
                    *Samples obtained from Queens Medical Centre microbiology department 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
Table 2- PCR-ribotype of isolates obtained from participant 01008 stools samples 463 
ID Specimen Sample collection date 
Number of Colonies 
obtained/typed* 
PCR-ribotype of 
isolate 
A 1st diagnostic sample 21/6/13 20/8 002 
B 2nd diagnostic sample 1/7/13 20/20 002 
C Week 0 (visit 1) RAPID sample 9/7/13 1/1 002 
D Relapse sample 1 19/7/13 8/5 002 
E Diagnostic sample post relapse sample 1 27/7/13 20/20 
E1-002 (7) 
E2- 014 (13) 
F Week 4 (visit 3) RAPID sample 7/8/13 15/14 002 
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G Week 12 (Visit 5) RAPID sample 2/10/13 20/20 002 
H Relapse sample after week 12 (visit 5) RAPID sample 4/1/14 20/20 014 
*In house capillary electrophoresis typing using a QIAxcel. Numbers in brackets of column five represent the 464 
frequency of that PCR-ribotype pattern 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
Table 3: PacBio Contig Assembly information from RT002 isolate A. 482 
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Contig PacBio BLAST identification Contig Size 
1 FN668944.1, Clostridium difficile BI9 chromosome 4,207,942bp
2 LN681537.1, Clostridium phage phiCD211, complete genome 140,450bp 
3 FN668942.1, Clostridium difficile BI1 plasmid pCDBI1, complete sequence 65,380bp 
4 GU949551.1, Clostridium phage phiCD6356, complete genome 52,160bp 
 483 
 484 
 485 
Strain Reference Position Type Reference Allele Count Coverage Frequency 
Average 
quality 
Coding region 
change 
Amino 
acid 
change 
C 319864 SNV A G 194 201 96.52 33.44 Choline binding protein A:c.6498A>G  
D 147783 SNV A T 189 192 98.44 36.37 
Aminobenzoyl-
glutamate transport 
protein:c.210T>A  
D 556338 Deletion A - 177 177 100.00 31.07 
Oligopeptide transport 
ATP-binding protein 
OppF 
(TC 
3.A.1.5.1):c.479delA 
p.Gln16
0fs 
D 2974068 SNV G A 210 233 90.13 36.21 
D 3762293 SNV C A 189 191 98.95 36.61 
DNA-directed RNA 
polymerase beta 
subunit (EC 
2.7.7.6):c.1465C>A 
p.Gln48
9Lys 
E1 147783 SNV A T 195 198 98.48 34.89 
Aminobenzoyl-
glutamate transport 
protein:c.210T>A  
E1 556338 Deletion A - 146 149 97.99 32.74 
Oligopeptide transport 
ATP-binding protein 
OppF 
(TC 
3.A.1.5.1):c.479delA 
p.Gln16
0fs 
E1 2974068 SNV G A 151 211 71.56 36.64 
E1 3762293 SNV C A 161 161 100.00 36.15 
DNA-directed RNA 
polymerase beta 
subunit (EC 
2.7.7.6):c.1465C>A 
p.Gln48
9Lys 
F 1181867 SNV G T 172 174 98.85 33.01 
FIG00512976: 
hypothetical 
protein:c.722C>A 
p.Thr24
1Asn 
F 1861424 SNV A G 158 168 94.05 31.75 
F 1861431 SNV G A 171 172 99.42 35.88 
F 2676955 SNV A C 231 233 99.14 35.90 
F 3762308 SNV A T 204 207 98.55 34.08 
DNA-directed RNA 
polymerase beta 
subunit (EC 
2.7.7.6):c.1475A>T 
p.Asp4
92Val 
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Table 4- Additional SNVs in genome of sequential RT002 isolates 486 
 487 
             Table 5. Frequency of all cultured RT002 isolates with and without rpoB SNVs  488 
ID Specimen Number of Colonies typed 
SNV 
present* 
A 1st diagnostic sample 8 - 
B 2nd diagnostic sample 20 - 
C Week 0 (visit 1) RAPID sample 1 - 
D Relapse sample 1 5 + (4) [C>A] - (1) 
E Diagnostic sample post relapse sample 1 7 + 
F Week 4 (visit 3) RAPID sample 14 + [A>T (13)] + [C>A (1)] 
G Week 12 (Visit 5) RAPID sample 20 + (10) [A>T] - (10) 
    * (-): absence of SNV, (+): presence of SNV. Numbers in brackets are the frequency of  489 
                  the isolates with or with the SNV. Square brackets identify which SNV was present. 490 
 491 
 492 
 493 
 494 
 495 
 496 
 497 
G 1181870 SNV G T 33 33 100 37.12 
FIG00512976: 
hypothetical 
protein:c.722C>A 
p.Thr24
1Asn 
G 1861429 SNV A G 21 21 100 32.95 
G 1861436 SNV G A 22 22 100 37.64 
G 2676961 SNV A C 12 12 100 38.67 
G 3762308 SNV A T 143 174 82.18 36.96 
DNA-directed RNA 
polymerase beta 
subunit (EC 
2.7.7.6):c.1475A>T 
p.Asp4
92Val 
G 3040149 SNV C A 21 33 63.64 38.24 
FIG00534171: 
hypothetical 
protein:c.13G>T 
p.Glu5* 
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 498 
 499 
 500 
 501 
 502 
Figure 1- A simplified study timeline indicating the collection of stool samples for the participants involved in 503 
the RAPID trial. 504 
 505 
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 A patient is enrolled on the RAPID trial, 
after resolution of CDI. The Patient is  
given rifaximin/ placebo therapy (4 
weeks) & stool sample collected (week 0 
stool) 
 
 
End of  
chaser  
therapy 
Follow up 
visit initiated 
and stool 
sample 
collected 
(week 4 
stool) 
Follow up 
 visit 
12 week follow 
up visit and 
stool sample 
collection (week 
12 stool) 
Trial  
Enrolment/ Randomisation 
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